Live tape
Top 8, mentions 7d6,458NVDA1,046 mentions▲ +0.09GOOGL1,034 mentions▲ +0.04NKE1,020 mentions+0.01LULU959 mentions▲ +0.03TSLA876 mentions▲ +0.06META558 mentions▲ +0.04QQQ483 mentions▲ +0.08AAPL482 mentions▲ +0.06

Equity · Healthcare

BMRN

BioMarin Pharmaceutical Inc. · NasdaqGS

$64.63 −2.88% 1D Finazon · prior-day close · Sep 8, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$80 $50 11 Jun 8 Sep

The line runs $55.52 on 11 June through $64.63 on 8 September, on a scale from $50 to $80. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of BMRN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $55.52 on 11 June 2026 through $64.63 on 8 September 2026.

Market cap $12.5B
P/E (TTM) 35.1
52-week range $49.67 – $70.23
Avg volume 259.4K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026

BMRN insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Sep 2026
Open-market buys 0
Open-market sells 1
Net sold $1.16M
Non-trade filings 0
Date Insider Type Shares Value
02 Sep 2026 Davis George Eric EVP, Chief Legal Officer Sell 17,557 $1.16M

BMRN reported financials

SEC EDGAR XBRL

BMRN reported revenue of $3.2B for the fiscal year ended 31 Dec 2025. Net income over the same period was $348.9M.

Figure Reported Period
Revenue $3.2B 31 Dec 2025 fiscal year
Net income $348.9M 31 Dec 2025 fiscal year
Diluted EPS $1.80 31 Dec 2025 fiscal year
Total assets $11.7B 30 Jun 2026 at period end
Total equity $6.3B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

BMRN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.23 —
31 Mar 2026 Q1 2026 $0.54 —
31 Dec 2025 FY 2025 $1.80 —
30 Sep 2025 Q3 2025 $-0.16 —
30 Jun 2025 Q2 2025 $1.23 —
31 Mar 2025 Q1 2025 $0.95 —
31 Dec 2024 FY 2024 $2.21 —
30 Sep 2024 Q3 2024 $0.55 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

BMRN institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a BMRN position for the quarter ended 30 Jun 2026 — a combined $1.1B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) +7.9% shares 7,616,563 $435.8M
AQR Capital Management Trimmed −25.8% shares 5,699,541 $322.5M
Millennium Management Trimmed −31.2% shares 2,071,816 $118.5M
Citadel Advisors Trimmed −75.1% shares 1,122,408 $64.2M
Balyasny Asset Management Held (±25%) −22.6% shares 1,054,613 $60.3M
Renaissance Technologies Trimmed −55.9% shares 451,871 $25.9M
Man Group Held (±25%) +18.8% shares 367,981 $21.1M
Bridgewater Associates Added +32.9% shares 274,911 $15.7M
Marshall Wace New position 97,300 $5.6M
D. E. Shaw & Co. Trimmed −67.4% shares 92,214 $5.3M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

BMRN fails-to-deliver

SEC CNS data

On 11 Aug 2026, 5,650 shares of BMRN failed to deliver (about $389K).

Settlement date Shares failed Notional % of shares out
11 Aug 2026 5,650 $389K 0.003%
07 Aug 2026 29,279 $1.8M 0.015%
04 Aug 2026 97 $6K <0.001%
30 Jul 2026 74 $5K <0.001%
29 Jul 2026 3,200 $199K 0.002%
27 Jul 2026 236 $14K <0.001%

Source: SEC fails-to-deliver (CNS) data